Display Settings:

Format

Send to:

Choose Destination

    J Immunol. 2006 Aug 15;177(4):2056-60.

    Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells.

    Hsiao FC, Lin M, Tai A, Chen G, Huber BT.

    Department of Pathology, Tufts University School of Medicine, 150 Harrison Avenue, Boston, MA 02111, USA.

    EBV, a ubiquitous human herpesvirus, is the causative agent of infectious mononucleosis and is associated with many carcinomas. We have previously shown that the EBV latent genes LMP-1 and LMP-2A (for latent membrane proteins 1 and 2A), transactivate a human endogenous retrovirus (HERV), HERV-K18, in infected B lymphocytes. The envelope (Env) protein of HERV-K18 encodes a superantigen that strongly stimulates a large number of T cells. In this study we report that HERV-K18 env is transactivated even earlier in the infection process, before the establishment of latency; namely, we found that EBV, through its interaction with its cellular receptor CD21, induces the HERV-K18 env gene in resting B lymphocytes. This transactivation is direct and immediate, as up-regulation of transcripts can be detected within 30 min after EBV exposure. Thus, EBV binding to human CD21 on resting B cells triggers the expression of an endogenous superantigen. The biological significance of this superantigen expression for the EBV life cycle is discussed.

    PMID: 16887963 [PubMed - indexed for MEDLINE]

    LinkOut - more resources

    Full Text Sources:

    Other Literature Sources:

    Molecular Biology Databases:

    Miscellaneous:

    Supplemental Content

    Click here to read Click here to read Click here to read Click here to read Click here to read Click here to read